{
  "docId": "019de075-7d9e-72c3-b72b-f46b67767727",
  "docSlug": "53c1bfc711678d7524a7d4316a5473e9",
  "documentTitle": "Chimerix | Investor Presentation Deck | 43 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 43,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "problem_statement",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes a Kaplan-Meier survival curve, an anatomical illustration of tumor locations, and a comparative table of clinical outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7d9e-72c3-b72b-f46b67767727/6",
  "deckHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727",
  "deckJsonHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727.json",
  "deckAnchorHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.315,
        "w": 0.235,
        "x": 0.425,
        "y": 0.165
      },
      "kind": "chart",
      "text": "Frontline H3 K27M DMG External analysis reported at SNO 2022",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8aca8824-84c1-443e-9719-ad9aa35e27e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.315,
        "w": 0.235,
        "x": 0.732,
        "y": 0.165
      },
      "kind": "image",
      "text": "Histone H3 Mutations in CNS Tumors",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52a78759-f344-4d6a-a205-c20b11308d6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.455,
        "w": 0.355,
        "x": 0.053,
        "y": 0.238
      },
      "kind": "list",
      "text": "H3 K27M mutation is predominantly found among diffuse midline gliomas (DMGs) in young adults and children. Frontline radiotherapy remains standard of care with transient benefit; resection often not feasible. DMGs harboring the H3 K27M mutation are WHO Grade IV; historically invariably lethal. Studies consistently indicate longer OS of ONC201-treated glioma patients relative to diverse external controls.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fb25613-15b3-46a9-9bb9-ee1f117be880",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.075,
        "y": 0.925
      },
      "kind": "source-note",
      "text": "1 Lulla RR et al. Sci Adv. 2016;2(3):e1501354 2 Sunjong Ji, B.S. et al, “Clinical efficacy and predictive biomarkers of ONC201 in H3 K27M-mutant diffuse midline glioma”, Society of Neuro-oncology 2022 3 The median OS was 5.1 months for the subset of patients with H3 K27M-mutant diffuse glioma excluding DIPG, CSF dissemination, spinal or leptomeningeal disease (N=12), OS at 12 mos was 25.0%, OS at 24 mos was 16.7%",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5cdd5982-3225-4739-b09d-d6190782882d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.355,
        "w": 0.542,
        "x": 0.425,
        "y": 0.555
      },
      "kind": "table",
      "text": "Company Sponsored Studies: Natural Disease History vs ONC201 Phase 2",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ae604598-2a15-4cd0-ba60-8a86e669e9d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.564,
        "x": 0.218,
        "y": 0.068
      },
      "kind": "title",
      "text": "H3 K27M-mutant diffuse glioma: high unmet need",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a34ad485-7057-4235-b23d-6a21cb1ce0be",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 6,
      "beatId": "52af8841-9ec7-4ea1-8b00-7e07d08f6e85",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "The deck identifies a high unmet need for H3 K27M-mutant diffuse glioma treatment",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 6,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "94af67d1-e80e-42ee-8d7b-9970ecae23e8",
      "evidence": "The deck presents data on the high unmet need and potential benefits of ONC201",
      "position": 0,
      "objective": "What is the cost of not treating H3 K27M-mutant diffuse glioma effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}